@article{discovery10064672,
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
           title = {Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect},
         journal = {Nature Medicine},
           pages = {225--228},
          volume = {25},
           month = {February},
            year = {2019},
        keywords = {Antisense oligonucleotide therapy, Clinical trials, Neurodegeneration, Oligo delivery},
          author = {Cideciyan, AV and Jacobson, SG and Drack, AV and Ho, AC and Charng, J and Garafalo, AV and Roman, AJ and Sumaroka, A and Han, IC and Hochstedler, MD and Pfeifer, WL and Sohn, EH and Taiel, M and Schwartz, MR and Biasutto, P and Wit, WD and Cheetham, ME and Adamson, P and Rodman, DM and Platenburg, G and Tome, MD and Balikova, I and Nerinckx, F and Zaeytijd, JD and Van Cauwenbergh, C and Leroy, BP and Russell, SR},
             url = {http://doi.org/10.1038/s41591-018-0295-0},
        abstract = {Photoreceptor ciliopathies constitute the most common molecular mechanism of the childhood blindness Leber congenital amaurosis. Ten patients with Leber congenital amaurosis carrying the c.2991+1655A{\ensuremath{>}}G allele in the ciliopathy gene centrosomal protein 290 (CEP290) were treated (ClinicalTrials.gov no. NCT03140969) with intravitreal injections of an antisense oligonucleotide to restore correct splicing. There were no serious adverse events, and vision improved at 3 months. The visual acuity of one exceptional responder improved from light perception to 20/400.}
}